Skip to main content
. 2018 Jul 7;36(33):5030–5036. doi: 10.1016/j.vaccine.2018.07.004

Fig. 1.

Fig. 1

Comparison of characteristics of H7 VLPs-WT and H7 VLPs-TM. (A) Negative staining electron microscopy of H7 VLPs-WT and H7 VLPs-TM. (B) Cleavage of HA in H7 VLPs-WT and H7 VLPs-TM. Western blot analysis was carried out after the purified H7 VLPs-WT and H7 VLPs-TM treated with increasing concentrations of TPCK-trypsin for 5 min. Lanes 1 and 2, H7 VLPs-WT and H7 VLPs-TM treated with 0 μg/ml TPCK-trypsin; Lanes 3 and 4, 0.2 μg/ml TPCK-trypsin treated; Lanes 5 and 6, 2 μg/ml TPCK-trypsin treated. (C) Non-reducing western blot to analyze the HA trimer of H7 VLPs-WT and H7 VLPs-TM (left panel). The histogram on the right showed the percentage of trimeric HA with the formula of (trimer)/(monomer + dimer + trimer). (D) Thermal resistance of H7 VLPs-WT and H7 VLPs-TM. HA assay was performed after H7 VLPs-WT and H7 VLPs-TM incubated at different temperatures (37, 46, 48, 50, 52, 54, 56 and 58 °C) for 30 min. The results of (B), (C), (D) were repeated for three times.